The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
Swiftmelt 1515-I meets performance requirements and secures skin attachment
The objective of this system is to shift the focus of measuring performance of hospitals from volume of services provided to value of healthcare services
ANSSI Wellness launches Asia’s premier and USA-patented ‘Spinal Decompression Treatment’ center in Nashik
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
The new facility will be able to handle four times as many patients as the previous facility.
Company to open new headquarters in 2024
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
Subscribe To Our Newsletter & Stay Updated
